Online pain education programs for people with Crohn's disease or ulcerative colitis
Tests two online pain education programs in adults with inflammatory bowel disease and chronic pain.
Plain-language title generated from the registry record
Registry title: Online Pain Education for Crohn's Disease and Ulcerative Colitis
Key facts
- Where
- Los Angeles, United StatesSee the site
Where in United States
- Cedars-Sinai Medical CenterLos Angeles, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cedars-Sinai Medical Center
- Trial code
- NCT07671313
- Record updated
- 26 October 2026
- Original description
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic pain. Each online program can be accessed on the patient's personal device, and will take up to 2 hours to complete. Clinical outcomes (pain intensity, pain interference, quality of life) will be assessed via online surveys at baseline and then weekly for 8-weeks post-treatment.Read full original descriptionShow less
Randomized Controlled Trial of Online Pain Education Programs for Inflammatory Bowel Disease
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic pain. Each online program can be accessed on the patient's personal device, and will take up to 2 hours to complete. Clinical outcomes (pain intensity, pain interference, quality of life) will be assessed via online surveys at baseline and then weekly for 8-weeks post-treatment.
Inclusion: Physician-confirmed diagnosis of Crohn's disease or ulcerative colitis; Chronic pain (visceral and/or somatic) related to IBD for at least 3 months; NIH PROMIS Pain Interference scale T-score ≥60; Medically stable, defined as:; No acute IBD-related hospitalization within the past 3 months; AND; No planned IBD surgery or planned therapeutic escalation within the next 2 months, including initiation of a new advanced therapy, dose escalation or switch of advanced therapy, or corticosteroid taper; Able to understand and complete questionnaires independently in English; Access to an internet-enabled device for online surveys and intervention access.
Exclusion: Current use of standing opioid medications, given the often severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia; Prior participation in cognitive behavioral therapy (CBT) specifically targeting chronic IBD-related pain; Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation; Taken any oral steroid medications for IBD or any other condition in the past 2 months (including prednisone, prednisolone, and methylprednisolone [Medrol]).